Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis

AB0520 Tocilizumab in rheumatoid arthritis – one year interim analysis of the non-interventional ichiban study:

(2014) C. Specker et al.   ANNALS OF THE RHEUMATIC DISEASES

FRI0323 Prospective Follow-Up of Tocilizumab Treatment in 1503 Patients with Refractory Rheumatoid Arthritis: Tolerance Data at 1 Year from the French Registry Regate (Registry – Roactemra)

(2014) J. Morel et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis

(2014) Jackie L Nam et al.   ANNALS OF THE RHEUMATIC DISEASES

The global burden of rheumatoid arthritis: estimates from the Global Burden of Disease 2010 study

(2014) Marita Cross et al.   ANNALS OF THE RHEUMATIC DISEASES

What is the future of targeted therapy in rheumatology: biologics or small molecules?

(2014) Attila Mócsai et al.   BMC Medicine

Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy

(2014) Norihiro Nishimoto et al.   Modern Rheumatology

The 2013 BSR and BHPR guideline for the use of intravenous tocilizumab in the treatment of adult patients with rheumatoid arthritis

(2014) Anshuman P. Malaviya et al.   RHEUMATOLOGY

Subcutaneous Tocilizumab Versus Placebo in Combination With Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis

(2014) Alan Kivitz et al.   ARTHRITIS CARE & RESEARCH

The Biology and Medical Implications of Interleukin-6

(2014) T. Tanaka et al.   Cancer Immunology Research

A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study)

(2013) Gerd R Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab

(2013) Joachim Listing et al.   ANNALS OF THE RHEUMATIC DISEASES

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

(2013) Cem Gabay et al.   LANCET

Work disability and state benefit claims in early rheumatoid arthritis: the ERAN cohort

(2013) D. F. McWilliams et al.   RHEUMATOLOGY

Phase III Study of the Efficacy and Safety of Subcutaneous Versus Intravenous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis

(2013) Atsushi Ogata et al.   ARTHRITIS CARE & RESEARCH

Systematic Review of Tocilizumab for Rheumatoid Arthritis: A New Biologic Agent Targeting the Interleukin-6 Receptor

(2012) Iris Navarro-Millán et al.   CLINICAL THERAPEUTICS

The role of tocilizumab in the management of rheumatoid arthritis

(2012) Zoe Ash et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase Iiib ALLOW study)

(2011) Jeffrey Kaine et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry

(2011) H. C. Leffers et al.   ANNALS OF THE RHEUMATIC DISEASES

Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries

(2010) X. Mariette et al.   RHEUMATOLOGY

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

(2009) G. Jones et al.   ANNALS OF THE RHEUMATIC DISEASES

Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study

(2009) G. M. Bartelds et al.   ANNALS OF THE RHEUMATIC DISEASES

Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO Registry

(2008) M L Hetland et al.   ANNALS OF THE RHEUMATIC DISEASES

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

(2008) P. Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study

(2008) Mark C. Genovese et al.   ARTHRITIS AND RHEUMATISM

The development of novel therapies for rheumatoid arthritis

(2008) Ling-dong Quan et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

(2008) Josef S Smolen et al.   LANCET